肺腺癌与骨转移:临床基因组分析和对预后因素的见解
Ahmed H Al Sharie1, Rami K Jadallah2, Mahmoud Z Al-Bataineh2
1Department of Pathology and Microbiology, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.
Cancer control : journal of the Moffitt Cancer Center
|March 25, 2025
概括
这项研究确定了与肺腺癌骨转移相关的关键临床和基因组因素,有助于癌症死亡的主要原因患者的风险分层.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 临床医学 临床医学
背景情况:
- 肺腺癌是全球癌症死亡的主要原因之一.
- 了解转移模式及其基因组驱动因素对于患者风险分层至关重要.
- 骨转移代表了肺腺癌管理中的重大临床挑战.
研究的目的:
- 为了研究肺腺癌中骨转移的临床遗传学特征.
- 确定与骨转移的发展相关的临床和基因组因素.
- 确定这些因素在患有骨转移的患者的预后价值.
主要方法:
- 对4064名肺腺癌患者进行了回顾性队列研究.
- 对患有骨转移和没有骨转移的患者进行比较分析,包括人口统计和基因组资料.
- 考克斯回归分析以确定独立的生存预后变量.
主要成果:
- 与骨转移相关的因素包括性别,并发转移和TP53,EGFR,KEAP1和MYC的突变.
- 骨转移亚队列中预后不良的指标包括年龄>75,女性性别,白人种族,特定的远程转移,以及EGFR (野生类型),KEAP1,MYC,KRAS和SMARCA4的突变.
- 确定了与肺腺癌骨转移相关的关键临床和基因组因素.
结论:
- 已经确定了与肺腺癌骨转移相关的关键临床和基因组因素.
- 这些发现为识别骨转移的高风险个体提供了洞察力.
- 建议在更大,多样化的队列中进行进一步验证,以提高概括性.
更多相关视频
07:44Practical Considerations in Studying Metastatic Lung Colonization in Osteosarcoma Using the Pulmonary Metastasis Assay
Published on: March 12, 2018
10.0K
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
992
相关概念视频
Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
84
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
84
